about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewRoles of lipoprotein receptors in the entry of hepatitis C virusAntiviral therapies for chronic hepatitis C virus infection with cirrhosisPrevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.Natural interferon-beta treatment for patients with chronic hepatitis C in JapanCurrent management of patients with hepatocellular carcinoma.Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase.Historical epidemiology of hepatitis C virus (HCV) in selected countries.Faldaprevir for the treatment of hepatitis C.Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.Automating crystallographic structure solution and refinement of protein-ligand complexes.Hepatitis C virus genotypes in Myanmar.Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
P2860
Q24628717-ACD0F3D9-539C-40C5-B39F-7E9F005EAC92Q26777338-AC37AA2F-0A6A-45DF-B15D-EACA60365362Q27022794-52656957-6076-44C7-8D86-8EF353204B91Q34998753-D0228F71-D98A-4600-B0AF-B2534054702DQ35668734-1E01F776-9DFB-4486-B6C7-11CC02A765A4Q35895363-DD794D6A-82D9-4BAF-9D08-E4396F74E6C0Q35905985-908DDAF1-775A-4D0C-A67D-6861DB65CA50Q35947900-CF9C96CC-DF9D-448A-A68B-E9CBF3D2408EQ37358287-FD402097-852F-46D6-A7F3-88D6B94F3330Q38203033-CFECFC10-CFB8-492F-8FE3-1E7FFA844762Q38370056-CCC9BACA-57B7-45CE-A507-B11946884BDEQ38849917-375A3001-D0E5-4336-B060-3586BF008576Q41576433-AA3B6DED-59C3-4945-A6DF-DC30710796A2Q41940007-5D10479E-F94F-4C71-B61D-3C7B84D2E52CQ42418913-46DBD342-0D68-44BF-86F2-D425D0255621Q46257659-F061D615-C145-44BD-BECA-0A8FD61EF8F9
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Treatment of hepatitis C virus infection in the future.
@en
Treatment of hepatitis C virus infection in the future.
@nl
type
label
Treatment of hepatitis C virus infection in the future.
@en
Treatment of hepatitis C virus infection in the future.
@nl
prefLabel
Treatment of hepatitis C virus infection in the future.
@en
Treatment of hepatitis C virus infection in the future.
@nl
P2093
P2860
P356
P1476
Treatment of hepatitis C virus infection in the future.
@en
P2093
Masao Omata
Osamu Yokosuka
Tatsuo Kanda
P2860
P2888
P356
10.1186/2001-1326-2-9
P577
2013-04-11T00:00:00Z
P5875
P6179
1001095563